ALPROLIX (eftrenonacog alpha), antihaemophilic factors (factor IX)

HAEMATOLOGY - New medicinal product

Opinions on drugs - Posted on Mar 10 2017

Inclusion

ALPROLIX and IDELVION are recombinant factor IX products indicated in the treatment of haemophilia B.
They are distinguished from the other available factor IX products by their pharmacokinetic properties, in particular by their extended half-life, which makes it possible to make the currently-practised prophylactic administration regimens easier.
In studies in previously treated patients, no factor IX inhibitors or thromboembolic events were observed.

Substantial

minor

Therapeutic use

Évaluation des médicaments

All our publications

My account